Gary F Bammert

US Patent:

20130022616, Jan 24, 2013

Filed:

Jun 28, 2012

Appl. No.:

13/536081

Inventors:

Gary F. Bammert - Portage MI, US
Steven A. Dunham - Kalamazoo MI, US

Assignee:

Pfizer Inc. - Madison NJ

International Classification:

C07K 16/24
A61K 39/395
A61P 37/08
A61P 17/00
A61P 17/04
A61P 17/06
A61P 11/00
A61P 29/00
C12N 15/63
C12P 21/02
C12N 1/21
C12N 1/19
C12N 1/15
C12N 5/10
G01N 33/577
G01N 33/566
C12N 15/13

US Classification:

4241581, 5303892, 53038823, 5303873, 536 2353, 5303879, 4353201, 435 696, 4352523, 4352542, 43525411, 435335, 43525233, 436501, 435 792

Abstract:

An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.

US Patent:

20220273793, Sep 1, 2022

Filed:

Feb 18, 2022

Appl. No.:

17/674991

Inventors:

- Parsippany NJ, US
Andrea J. Gonzales - Portage MI, US
Timothy J. Fleck - Scotts MI, US
Katelyn S. Vroman - Mattawan MI, US
Gary F. Bammert - Portage MI, US

International Classification:

A61K 39/395
C07K 16/24
A61K 47/64
A61P 17/04

Abstract:

The present invention provides an IL-31 horse pruritus model which confirms that IL-31 induces itch in horses and can be used to assess whether certain test compounds can block or reduce the itch in treated horses. This experimental model includes administering equine IL-31 to horses to produce a pruritic response; quantitatively measuring pruritic responses in the horses which were administered equine IL-31; administering a candidate horse IL-31 inhibitor; and assessing the effectiveness of the candidate horse IL-31 inhibitor in reducing pruritic behavior in the treated horses by challenging the horses with equine IL-31 following the administration of the candidate horse IL-31 inhibitor.

US Patent:

20190359702, Nov 28, 2019

Filed:

Aug 14, 2019

Appl. No.:

16/540483

Inventors:

- PARSIPPANY NJ, US
JAMES TAYLOR CURRY - KALAMAZOO MI, US
ROBERT B. MCCALL - PORTAGE MI, US
WILLIAM R. HUMPHREY - DELTON MI, US
ANDREA JOY GONZALES - PORTAGE MI, US
GARY FRANCIS BAMMERT - PORTAGE MI, US
STEVEN ALAN DUNHAM - KALAMAZOO MI, US

International Classification:

C07K 16/24
G01N 33/68

Abstract:

An IL-31 dog pruritus model is provided. This model comprises administering canine IL-31 to dogs to produce a pruritic response; quantitatively measuring pruritic responses in the dogs which were administered canine IL-31; administering a candidate dog IL-31 inhibitor; and assessing the effectiveness of the candidate dog IL-31 inhibitor in reducing prurtic behavior in the treated dogs by challenging the dogs with canine IL-31 following the administration of the candidate dog IL-31 inhibitor.

US Patent:

20190092854, Mar 28, 2019

Filed:

Dec 5, 2018

Appl. No.:

16/210228

Inventors:

- Parsippany NJ, US
Gregory Fici - Galesburg MI, US
Gary Francis Bammert - Portage MI, US
Steven Alan Dunham - Kalamazoo MI, US

International Classification:

C07K 16/24
G01N 33/68
A61K 39/00

Abstract:

A cell-based assay for assessing the functional activity of a canine or feline IL-31 inhibitor candidate is provided. Such a canine or feline IL-31 inhibitor candidate can be an isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.